Enhancing Emotion Regulation in Youth through Neuro-feedback Training: An Adjunctive Approach to Standard In-Patient Multimodal Psychotherapy – a Pilot Study

Enhancing Emotion Regulation in Youth through Neuro-feedback Training: An Adjunctive Approach to Standard In-Patient Multimodal Psychotherapy – a Pilot Study - NEMOTRAIN

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037522

Enrollment

Registered

2025-07-25

Start date

2026-05-18

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Young adults (18-30 years) receiving inpatient psychiatric/psychotherapeutic treat-ment at Clinic Barmelweid, presenting with difficulties in emotion regulation and/or dissociative symptoms.

Interventions

Group 1: Neurofeedback-Group (NFB-Group) Group 2: Treatment as Usual-Group (TAU-Group)

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: - Between 18 and 30 years old - Patients in inpatient psychotherapy at Barmelweid Clinic - DERS-16 score equal to or higher than 34 points

Exclusion criteria

Exclusion criteria: - Diagnosis of schizophrenia or bipolar disorder - History of epilepsy or cerebral seizures - Body Mass Index below 15 kg/m²

Design outcomes

Primary

Measure	Time frame
Primary outcomes are feasibility data: - Recruitment rate (number of eligible participants divided by the number of screened participants) - Retention rate (number of participants who complete the study divided by the number of enrolled participants =80%) - Protocol adherence (number of completed sessions divided by the number of planned sessions =90%) - Data quality (percentage of usable EEG/fNIRS recordings =85%) - Adverse events (frequency and severity of reported side effects)	—

Measure

Time frame

Primary outcomes are feasibility data: - Recruitment rate (number of eligible participants divided by the number of screened participants) - Retention rate (number of participants who complete the study divided by the number of enrolled participants =80%) - Protocol adherence (number of completed sessions divided by the number of planned sessions =90%) - Data quality (percentage of usable EEG/fNIRS recordings =85%) - Adverse events (frequency and severity of reported side effects)

—

Secondary

Measure	Time frame
Secondary Endpoints: - DERS-16 and SEK-27 scores (at baseline and changes between baseline and post-intervention (after week 6)) - A-DES-II scores (at baseline and changes between baseline and post-intervention (after week 6)) - Evaluation of the clinic’s standard diagnostics (at baseline and changes be-tween baseline and post-intervention) - Occipital alpha activity measured by EEG/fNIRS (at baseline and changes be-tween baseline and post-intervention (week 6)) - Participant satisfaction scores from session feedback forms	—

Measure

Time frame

Secondary Endpoints: - DERS-16 and SEK-27 scores (at baseline and changes between baseline and post-intervention (after week 6)) - A-DES-II scores (at baseline and changes between baseline and post-intervention (after week 6)) - Evaluation of the clinic’s standard diagnostics (at baseline and changes be-tween baseline and post-intervention) - Occipital alpha activity measured by EEG/fNIRS (at baseline and changes be-tween baseline and post-intervention (week 6)) - Participant satisfaction scores from session feedback forms

—

Countries

Switzerland

Contacts

Public ContactPatrick Köck

Klinik Barmelweid AG

patrick.koeck@barmelweid.ch+41 (0) 62 857 20 29

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026